Zandu Balm's Legacy Brand Strategy in Pain Relief

Industry & Competitive Context

The Indian topical pain-relief category encompassing balms, ointments, gels, and sprays sits at the intersection of Ayurveda-led traditional medicine and modern OTC (over-the-counter) personal care. Industry estimates place the India topical pain balm and ointment market at USD 890 million in 2025, projected to grow to approximately USD 1.72 billion by 2033 at a CAGR of 8.5 percent. The category is shaped by herbal innovation, dual-action cooling-and-heating formulations, e-commerce expansion, and fast-absorbing formats, with North India showing the highest usage of herbal balms while South India is cited as the fastest-growing region. India Topical Pain Balm & Ointment Market Size and Share Analysis 2025-2033 +2

Zandu Balm competes within this category against Amrutanjan, Tiger Balm, Dabur, Patanjali Ayurved, and Blue Cross Laboratories, among others, as identified in recognized industry market reports. Within Emami's own portfolio, Zandu Balm sits alongside Mentho Plus Balm, a brand Emami had launched internally in the pain-management space prior to the Zandu acquisition.

Brand Situation Prior to Acquisition

Zandu traces its origins to 1910, when Jugatram S. Vaidya founded Zandu Pharmaceutical Works to manufacture Ayurvedic medicines based on classical texts such as the Charak Samhita, Sushruta Samhita, and Bhaishajya-Ratnavali, later joined by Mathuradas B. Parikh. The company was converted into a public limited entity in 1919, according to the official company history published by Zandu itself. Over subsequent decades, Zandu Pharmaceutical Works diversified into allopathic manufacturing and biological preparations, but the flagship consumer product to emerge from this heritage was Zandu Balm an ayurvedic pain-relief balm formulated with menthol, camphor, eucalyptus oil, and gaultheria oil, sold in its distinctive yellow tin. Zandufoundation

By the mid-2000s, the founding families' internal governance had become a point of friction. According to a documented academic case record, the two founding families of Zandu the Vaidyas, who supplied Ayurvedic technical expertise, and the Parikhs, who brought trading and business acumen fell into dispute, as the Vaidya descendants were denied a board director position by the Parikhs and eventually sold their stake to Emami, precipitating a contested takeover. Caseresearchaima

Separately, Emami itself had already been present in the pain-balm category for two decades. According to company material cited in the acquisition-era coverage, Emami had identified the potential of the pain-management segment as early as 1987, introducing Mentho Plus Balm followed by Himani Fast Relief, meaning Zandu was acquired by a strategic buyer with existing category expertise rather than a diversifying outsider.

Strategic Objective

Emami's acquisition of Zandu was a category-consolidation move rather than a diversification bet. In 2008, Emami Limited acquired The Zandu Pharmaceutical Works Limited for Rs 750 crore, and in 2009 merged Zandu's FMCG business into Emami Limited. The takeover was contested: Zandu's promoters alleged that Emami had violated takeover regulations, and regulatory approval was delayed until October 2008 due to the resulting legal proceedings. Despite this friction, the acquisition helped Emami exceed its own turnover target of Rs 1,000 crore for 2009–10 and helped it retire debt taken on for the purchase. Emami FMCG | Emami Group +2

The strategic objective was therefore twofold: (i) acquire outright leadership in the pain-balm category by combining Emami's existing Mentho Plus/Himani Fast Relief franchise with Zandu's dominant legacy brand equity, and (ii) apply Emami's modern FMCG distribution and marketing muscle to a brand that had strong heritage trust but comparatively underdeveloped reach under its founding-family ownership.

Campaign Architecture & Execution: Preserving Equity While Modernizing Reach

A defining feature of Emami's post-acquisition strategy was continuity of core brand assets rather than reinvention. The official Emami brand page states that Zandu continues to position itself around bringing pure, authentic, and effective Ayurvedic remedies at affordable prices, in strict compliance with classical Ayurvedic scriptures, combined with modern manufacturing technology. This "heritage-plus-modern-technology" framing has remained the brand's core narrative both before and after the ownership change, according to the company's own current brand communication. Emami -

On the product-architecture side, Emami extended the core Zandu Balm formulation into adjacent formats and strength tiers including Zandu Balm Ultra Power and Zandu Gel rather than replacing the flagship product, based on product listings on Emami's own distribution channels and trade-facing product catalogues.

A notable, well-documented execution event illustrates Emami's approach to protecting and opportunistically activating Zandu's brand equity in popular culture. In 2010, the song "Munni Badnam Hui" from the Bollywood film Dabangg referenced the Zandu brand name in its lyrics. According to Business Standard, it took Emami, the owners of Zandu Balm, almost two months to take the film's producers to court over what it called unauthorised use of the brand name in the song, even though many observers felt the dance number had done more for Zandu's brand equity than the company's own advertising campaigns combined. The matter was resolved without prolonged litigation: the dispute was settled within days, with actor Malaika Arora Khan who had also co-produced the film agreeing to star in a dedicated advertisement promoting Zandu. Business Standard further reported that Emami's founders claimed the company was the first FMCG firm in India to attempt in-film brand placement, dating back to the 1983 Rajesh Khanna film "Agar Tum Na Hote," and that the company was reportedly considering replicating the in-song brand-integration approach with other brands and in regional-language films. Dabangg moment for Zandu Balm +2

This episode is publicly documented and offers a legitimate strategic lens: rather than treating unauthorized cultural appropriation of the brand name purely as an infringement risk, Emami converted a legal dispute into a fresh, culturally resonant advertising asset featuring a high-visibility Bollywood star while the underlying legal action itself signaled active trademark protection of a century-old asset.

Positioning & Consumer Insight

Zandu Balm's positioning has consistently rested on two pillars documented across company and industry sources: (1) Ayurvedic authenticity and trust built over a century, and (2) functional efficacy against everyday ailments headache, body ache, cold, and joint pain. Trade-facing product descriptions consistently describe Zandu Balm as India's number-one pain-relieving balm, a brand that has become a generic name for balms among many consumers, and a trusted remedy for over a hundred years, with distribution reportedly reaching more than 5 crore Indian households and over 13 lakh retail outlets across the country. While these figures originate from trade/distributor-facing product listings rather than an audited corporate disclosure, they are consistent with the brand's documented market-leadership position. indiamartindiamart

The underlying consumer insight implicit in the retention of the brand's original yellow-tin packaging, ingredient list, and Ayurvedic framing after the Emami acquisition is that trust in a legacy pain-relief remedy is a slow-built, intergenerational asset that a new corporate owner risks eroding through overt reinvention. Emami's own brand page continues to anchor Zandu's positioning in classical Ayurvedic scripture compliance rather than in claims of scientific reinvention, indicating a deliberate strategic choice to compete on heritage authenticity rather than technological novelty within this sub-segment of the category.\

Media & Channel Strategy

No verified public information is available on Zandu Balm's specific media mix, digital-versus-television spend allocation, or channel-wise campaign performance metrics. The one credible, documented media/channel event available is the in-film/in-song brand placement and subsequent dedicated advertisement described above, which Business Standard reported as part of a broader company claim to pioneering in-film brand integration in Indian FMCG marketing.

Business & Brand Outcomes

Documented, source-attributable outcomes are limited but meaningful:

• Category share: Business Standard reported in 2010 that Zandu continued to retain over 45 percent share of the pain-relief balm segment, which includes rivals such as Amrutanjan and Tiger Balm, following its post-acquisition repositioning under Emami.

  
  

• Growth trajectory (recent): According to Statista, sourcing Emami's own disclosures, the combined pain-management range comprising Zandu and Mentho Plus balm grew 6 percent in fiscal year 2024, a deceleration from 29 percent growth recorded in fiscal year 2023.

  
  

• Category tailwind: Independent industry research estimates the broader Indian topical pain balm and ointment market will nearly double in value from USD 890 million in 2025 to approximately USD 1.72 billion by 2033, suggesting continued structural demand growth in the category Zandu competes within.

  
  

Strategic Implications

The Zandu Balm case illustrates several transferable principles relevant to legacy-brand stewardship following an acquisition:

First, equity preservation over reinvention can be a deliberate strategic choice, not merely inertia. Emami's retention of Zandu's original packaging, ingredient story, and Ayurvedic-heritage narrative as reflected in its own current brand communications — suggests a conscious decision to treat the acquired brand's century-old trust as the primary asset to protect, layering modern distribution and manufacturing scale on top rather than beneath a repositioned identity.

Second, brand protection and cultural opportunism are not mutually exclusive. The Dabangg/"Munni Badnam" episode shows a company simultaneously defending its trademark through legal action and converting the resulting negotiation into a high-visibility advertising asset — a documented instance of turning an infringement dispute into incremental brand equity at what was likely a fraction of the cost of an equivalent celebrity-led campaign built from scratch.

Third, category consolidation through acquisition can combine a challenger brand's existing category expertise (Emami's Mentho Plus/Himani Fast Relief, in place since 1987) with an acquired legacy leader's consumer trust, producing combined category share materially higher than either brand could sustain independently evidenced by the reported 45 percent segment share retained post-acquisition.

Finally, the case underscores the limits of publicly available brand-level data for privately disclosed FMCG portfolios: much of what can be assessed about Zandu Balm's marketing execution rests on a small number of well-documented events (the acquisition terms, the takeover dispute, and the Dabangg litigation) rather than a continuous, granular record of campaign-level strategy, underscoring the importance of triangulating corporate statements, financial disclosures, and credible news reporting when constructing brand strategy case studies for legacy Indian FMCG brands.

Discussion Questions

1. When a challenger brand (Mentho Plus) and a newly acquired category leader (Zandu Balm) sit within the same parent portfolio, what criteria should guide investment allocation between them — and does the FY23–FY24 growth deceleration reported by Statista suggest maturity, competitive pressure, or reduced marketing investment?

   
   

2. Emami chose to retain Zandu Balm's original packaging, formula, and Ayurvedic narrative rather than modernizing the brand identity after acquisition. Under what conditions is "preserve, don't reinvent" the correct post-acquisition brand strategy, and when might it become a liability?

   
   

3. The Dabangg/"Munni Badnam Hui" episode shows a trademark dispute resolved through a celebrity-fronted advertisement rather than prolonged litigation. What does this reveal about the trade-offs between legal brand protection and opportunistic cultural marketing, and how replicable is this playbook across other legacy brands?

   
   

4. With the Indian topical pain balm and ointment market projected to nearly double by 2033, largely on the back of herbal innovation and e-commerce expansion, what strategic risks does a heritage-anchored brand like Zandu Balm face if it does not visibly innovate in format (gel, spray, roll-on) or channel (D2C, quick commerce)?

   
   

5. Given that verifiable public data on Zandu Balm's standalone financial performance is limited, what alternative, credible signals (distribution reach, category share, growth-rate disclosures, competitive benchmarking) should a strategist rely on to assess a legacy sub-brand's health within a diversified FMCG portfolio?